+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lymphoma"

From
From
From
From
Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2023-2027 - Product Thumbnail Image

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2023-2027

  • Report
  • February 2023
  • 166 Pages
  • Global
From
From
From
From
From
From
Market Spotlight: Mantle Cell Lymphoma - Product Thumbnail Image

Market Spotlight: Mantle Cell Lymphoma

  • Report
  • April 2021
  • 51 Pages
  • Global
From
From
Immuno-oncology Development Trends and Opportunities - Product Thumbnail Image

Immuno-oncology Development Trends and Opportunities

  • Report
  • November 2018
  • 258 Pages
  • Global
From
Loading Indicator

Lymphoma is a type of hematological malignancy that originates in the lymphatic system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. Lymphomas can be either Hodgkin's or non-Hodgkin's, and can be either indolent or aggressive. Treatment options for lymphoma include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies. The lymphoma market is a subset of the larger hematology market, which includes treatments for a variety of blood-related diseases. The lymphoma market is driven by the increasing prevalence of the disease, as well as the development of new treatments. Companies in the lymphoma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Pfizer. Show Less Read more